MedTrace Logo

Vietnam Cryptococcal Retention in Care Study Version 1.0

NCT02334670 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2612

Last updated 2017-09-13

No results posted yet for this study

Summary

It is hypothesized that implementing plasma CrAg screening in clinics providing routine HIV care will enable identification of Vietnamese adult patients with advanced HIV (CD4 ≤100 cells/μL) who have early cryptococcal disease, enable prompt preemptive treatment with high-dose fluconazole, and improve survival.

Conditions

  • Meningitis, Cryptococcal
  • Central Nervous System Fungal Infections
  • Central Nervous System Infections
  • Meningitis, Fungal

Interventions

DRUG

Fluconazole

HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.

Sponsors & Collaborators

Principal Investigators

  • Nguyen Van Kinh, MD, PhD · National Hospital for Tropical Diseases

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-14
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02334670 on ClinicalTrials.gov